Ultrasound Evaluation of Therapeutic Response to Tofacitinib and Upadacitinib in Patients with Rheumatoid Arthritis—Real-Life Clinical Data

<b>Background</b>: In recent years, musculoskeletal ultrasonography (MSUS) has established itself as a reliable method for evaluating disease activity in combination with clinical examination and laboratory tests. <b>Objectives</b>: In this pilot study, we aimed to evaluate t...

Full description

Bibliographic Details
Published in:	Biomedicines
Main Authors:	Vladimira Boyadzhieva, Konstantin Tachkov, Soner Emin, Zhaklin Apostolova, Rumen Stoilov, Guenka Petrova, Nikolay Stoilov
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Subjects:	tofacitinib upadacitinib musculoskeletal ultrasonography rheumatoid arthritis disease activity
Online Access:	https://www.mdpi.com/2227-9059/13/6/1339

Similar Items

Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells
by: Viktoria Golumba‐Nagy, et al.
Published: (2023-10-01)

Tofacitinib in Patients with Rheumatoid Arthritis: Single-center Experience Rheumatoid Arthritis and Tofacitinib
by: Müçteba Enes Yayla, et al.
Published: (2020-04-01)

Efficacy of tofacitinib on rheumatoid arthritis: A retrospective single-center cohort study
by: Yuhui Qi, et al.
Published: (2023-09-01)

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study
by: Robert Gilmore, et al.
Published: (2025-07-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Are the goals of therapy achievable in patients with rheumatoid arthritis receiving upadacitinib in real clinical practice?
by: V. N. Amirjanova, et al.
Published: (2022-07-01)

Seronegative cutaneous rheumatoid nodules with positive response to tofacitinib
by: Matthew Helm, MD, et al.
Published: (2024-08-01)

Effective Treatment of Prurigo Nodularis With Oral Tofacitinib: A Case Report
by: Nikoo Mozafari
Published: (2025-03-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris—A Case Report
by: Mahsa Taremi, et al.
Published: (2025-10-01)

The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
by: E. L. Nasonov, et al.
Published: (2020-11-01)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019-10-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Budget impact of upadacitinib in patients with moderate to severe rheumatoid arthritis in Argentina
by: Natalia Espínola, et al.
Published: (2024-06-01)

Letter to the Editor Regarding the Article "Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials"
by: YanRan Qiu, et al.
Published: (2025-03-01)

The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”)
by: V. N. Amirjanova, et al.
Published: (2021-10-01)

Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
by: Ieva Lingytė, et al.
Published: (2024-09-01)

Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment
by: Yi Lu, et al.
Published: (2023-05-01)

A Case Series Report on the Effect of Tofacitinib on Joint Inflammation and Gut Microbiota Composition in Psoriatic Arthritis Patients Naive to Biologic Agents
by: Andrea Picchianti Diamanti, et al.
Published: (2024-11-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6
by: Piero Ruscitti, et al.
Published: (2022-05-01)

Reactivation of latent tuberculosis infection following initiation of tofacitinib therapy for rheumatoid arthritis: A case report
by: Nishant Johri, et al.
Published: (2023-12-01)

Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis
by: Monika Czókolyová, et al.
Published: (2022-10-01)

Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials
by: Nie Liu-yan, et al.
Published: (2023-06-01)

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes
by: Nina Yao, et al.
Published: (2021-10-01)

An effective strategy with tofacitinib for the management of focal myositis with rheumatoid arthritis: a case report
by: Jing Pan, et al.
Published: (2024-12-01)

Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup—A Multicenter Study
by: Marta Priora, et al.
Published: (2024-12-01)

Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach
by: Boglárka Soós, et al.
Published: (2022-11-01)

Tofacitinib: efficiency and safety in long-term use
by: N. V. Chichasova
Published: (2019-03-01)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
by: Cristina Martinez-Molina, et al.
Published: (2024-02-01)

Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab
by: Seong-Kyu Kim, et al.
Published: (2023-04-01)

Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
by: Gustavo Citera, et al.
Published: (2023-11-01)

Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries
by: Antonio Vitale, et al.
Published: (2024-08-01)

Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries
by: Antonio Vitale, et al.
Published: (2024-09-01)

Efficacy and safety of Tofacitinib in patients with active rheumatoid arthritis resistant to conventional therapy: Preliminary results of an open-label clinical trial
by: E. L. Luchikhina, et al.
Published: (2016-06-01)

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment
by: Cristina Martinez-Molina, et al.
Published: (2025-03-01)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
by: Jürgen Wollenhaupt, et al.
Published: (2019-04-01)

Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)
by: G. I. Gridneva, et al.
Published: (2022-12-01)

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study
by: Andrew Östör, et al.
Published: (2025-04-01)